BRCA2 and Familial prostate cancer: Based on germline studies conducted in men with metastatic disease, DNA repair alterations are expected in approximately 12–17% of the time, more often including BRCA2, ATM, and CHEK2 genes, which is significantly higher than the incidence of men with localized prostate cancer or with family history of prostate cancer [8,11].